Int Urol Nephrol. 2026 Apr 1. doi: 10.1007/s11255-026-05099-z. Online ahead of print.
ABSTRACT
BACKGROUND: Chronic Kidney Disease (CKD) is a major global health problem, burdening more than 650 million people worldwide and exposing them to the risk of aortic stenosis (AS). The present study responds to the urgent need to assess the safety and effectiveness of aortic valve replacement (AVR) interventions young adults with CKD, who tend to be excluded from randomized trials.
METHODS: We analyzed the in-hospital outcomes of transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in a young adult population with chronic kidney disease (CKD) using the National Inpatient Sample (NIS) database. This large, publicly available United States inpatient healthcare database allowed cross-sectional analysis of hospital admissions during 2018-2020. The population included patients under the age of 65 with a primary or secondary CKD diagnosis who underwent TAVR or SAVR procedures. Baseline factors and in-hospital outcomes, such as mortality rates, hospital costs, and hospital stay, were compared between the TAVR and SAVR groups using statistical analysis, adjusting for these baseline factors.
RESULTS: The 11,315 young adults with CKD trial revealed that TAVR was associated with comparable risk of in-hospital death, reduced length of hospital stay, and decreased hospital charges in comparison to SAVR. TAVR was also associated with reduced risk of acute kidney injury, cardiogenic shock, and venous thromboembolism complications.
CONCLUSIONS: In conclusion, TAVR presents a favorable alternative to SAVR for young adults with CKD. These findings contribute strong evidence to guide clinical decision-making and improve care for this complex patient population.
PMID:41922882 | DOI:10.1007/s11255-026-05099-z
